The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Sponsor
The First People's Hospital of Changzhou
Study ID
NCT02493582
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Adenocarcinoma of Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Cytokine-Induced Killer Cells — BIOLOGICAL
    CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
  • Apatinib — DRUG
    Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.

Study Details

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR

Key Dates

Start date
Jul 31, 2015
Status verified
Feb 2016
Primary completion
Jul 31, 2030
Completion
Jul 31, 2033

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: Apatinib alone
    Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
  • Experimental: Apatinib+CIK
    Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: 3 months ]

Related Studies